CN111018876B - Application of phthalide dimer in preparation of vasodilation drugs - Google Patents
Application of phthalide dimer in preparation of vasodilation drugs Download PDFInfo
- Publication number
- CN111018876B CN111018876B CN201911422088.5A CN201911422088A CN111018876B CN 111018876 B CN111018876 B CN 111018876B CN 201911422088 A CN201911422088 A CN 201911422088A CN 111018876 B CN111018876 B CN 111018876B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- phthalide
- volume ratio
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title abstract description 18
- 230000024883 vasodilation Effects 0.000 title abstract description 17
- 125000005506 phthalide group Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 123
- -1 phthalide dimer compound Chemical class 0.000 claims abstract description 19
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims abstract description 17
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 64
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 230000014759 maintenance of location Effects 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 238000011894 semi-preparative HPLC Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000003071 vasodilator agent Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 241000244365 Ligusticum sinense Species 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 238000004296 chiral HPLC Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004237 preparative chromatography Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 125000001033 ether group Chemical group 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 26
- 239000000178 monomer Substances 0.000 abstract description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract description 4
- 239000000480 calcium channel blocker Substances 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract description 3
- 229940002612 prodrug Drugs 0.000 abstract description 3
- 239000000651 prodrug Substances 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 3
- 230000003042 antagnostic effect Effects 0.000 abstract description 2
- 238000006352 cycloaddition reaction Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 241000112528 Ligusticum striatum Species 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 208000006906 Vascular Ring Diseases 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100039397 Gap junction beta-3 protein Human genes 0.000 description 6
- 101100061841 Homo sapiens GJB3 gene Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 102100025284 Gap junction alpha-9 protein Human genes 0.000 description 5
- 101000858028 Homo sapiens Gap junction alpha-9 protein Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000304 vasodilatating effect Effects 0.000 description 4
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000005100 correlation spectroscopy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 2
- 238000007106 1,2-cycloaddition reaction Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- RSKPJCDZAFMWHH-BAQGIRSFSA-N 3-[(Z)-but-1-enyl]-3H-2-benzofuran-1-one Chemical compound C(=C/CC)/C1OC(=O)C2=CC=CC=C12 RSKPJCDZAFMWHH-BAQGIRSFSA-N 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003804 effect on potassium Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GDPWNVYHUPKTDG-WLBXSOTESA-N neodiligustilide Chemical compound CCCC([C@]1(C=O)C=CCCC11/C(\O)=C/CCC)[C@]1(C1=C2C=CCC1)OC2=O GDPWNVYHUPKTDG-WLBXSOTESA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention aims to provide an application of a phthalide dimer compound, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof in preparing vasodilation drugs. The phthalide dimer compound is formed by cycloaddition of two phthalide monomers through [ 2+2 ], and the formed phthalide dimer comprises 1 or 2 spiro atoms, wherein the phthalide monomers are selected from the following structures. The compound has excellent vasodilation activity, is superior to a monophthalide compound, plays a role in vasodilation by antagonizing the Cav1.2 receptor, provides a new choice for clinically screening and/or preparing vasodilation medicaments, provides a new molecular template for designing novel calcium antagonist medicaments, and has excellent clinical application prospect.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of a phthalide dimer in preparation of a vasodilator medicine.
Background
Cardiovascular disease (Cardiovascular Disease) is the disease with the highest global morbidity and mortality at present, seriously affects the quality of life of patients and creates a huge economic and social burden. The disease is a heart and vascular disease, which is generally referred to as ischemic or hemorrhagic disease of heart and whole body tissue caused by hyperlipidemia, atherosclerosis, hypertension and the like, and comprises various diseases such as coronary heart disease, myocardial infarction, cerebral vasospasm and the like.
With the progressive younger age of the cardiovascular disease onset population, morbidity and mortality are also increasing, and control of the disease state is becoming increasingly important. At present, most of medicines show obvious toxic and side effects when treating diseases, often damage liver and kidney, and easily cause complications such as heart, brain, kidney and the like when serious, and have obvious toxic and side effects. For example, prolonged administration of dihydropyridines may cause arrhythmia or myocardial infarction, and muscle poisoning may be caused by administration of other drugs. Therefore, there is an urgent need to find an innovative medicament with good curative effect and little toxic and side effects. Therefore, searching for monomer components with better curative effects from natural plants such as traditional Chinese medicines becomes an important source of the innovative medicines, and many traditional Chinese medicine extracts and the monomer components thereof have been screened to have antihypertensive and vasodilatory effects at present, wherein part of monomer compounds have been studied as potential therapeutic agents for treating hypertension and related complications thereof.
Calcium channel blockers are one of the most effective drugs currently used to treat primary hypertension. Long-term drugs, such as amlodipine, can continuously and gently lower blood pressure levels. Cav1.2 is the primary gating site for calcium ions to enter vascular cells. Calcium ions enter the cell through the cav1.2 channel, acting as a second messenger, regulating various physiological functions of the cell, such as contraction and gene expression. In resistance-type blood vessels, the cav1.2 channel plays an important role in blood pressure regulation. The Cav1.2 channel is widely expressed in blood vessels and hearts, and plays roles in regulating and controlling blood pressure, heart rate, contraction and the like. L-type calcium channel blockers such as dihydropyridines have been shown to be effective drugs for treating hypertension.
Ligusticum wallichii is a dried rhizome of Ligusticum wallichii (Ligusticum chuanxiong Hort.) belonging to Umbelliferae, and is a well-known Chuan-producing area medicinal material. Has the effects of activating blood circulation to dissipate blood stasis, promoting qi circulation to resolve depression, dispelling wind and relieving pain, is clinically used for treating headache, liver depression and qi stagnation syndrome, various blood stasis syndromes and the like, and is recorded in Bencao Meng ban: ascending head and eyes, descending blood sea, activating liver meridian and qi in blood. Modern researches have shown that Ligusticum wallichii has remarkable pharmacological activity on respiratory system, cardiovascular system, urinary system and the like. The main components of the rhizoma ligustici wallichii comprise phthalide, alkaloid, organic phenolic acid, polysaccharide and the like. The phthalide compound is used as the main active ingredient of the ligusticum wallichii, has obvious regulation effect on cardiovascular and cerebrovascular systems, nervous systems and the like, and is studied and presumed to be the main material foundation of the ligusticum wallichii for treating blood stasis or cardiovascular and cerebrovascular diseases. Moreover, researches show that the phthalide medicine can penetrate through the blood brain barrier, which is probably the drug effect substance foundation of the ligusticum chuanxiong, which is especially good for treating headache. However, vasodilation is a main treatment mode for cardiovascular diseases such as coronary heart disease, angina pectoris and myocardial infarction at present, and researches show that ligustilide, senkyunolide A and other monophthalide have vasodilation activity, but the related activity of the phthalide dimer is not reported yet, and needs to be further researched.
The traditional medicinal parts of the ligusticum wallichii are rhizome, and overground parts (stems and leaves) accounting for 75 percent of the fresh weight of the whole plant are discarded, so that not only is the resource waste and the environmental pollution caused, but also the sustainable utilization of the traditional Chinese medicine resource is not facilitated. However, the stem and leaf of Ligusticum wallichii is used in ancient times, the stem and leaf of Ligusticum wallichii is called Mi rui, shen nong Ben Cao Jing (Shen nong's herbal medicine meridian) records "main cough and reverse, calm the convulsion, expel evil and dislike, remove the parasitic and ghost to fully recover, remove three worms and activate the spirit after long-term administration. Based on the long history of folk eating of the stem leaves of the ligusticum wallichii and the activity characteristics of the phthalide components, the invention starts from the vasodilatation effect of the phthalide components of the stem leaves of the ligusticum wallichii, so as to screen the phthalide active components with novel structure and obvious activity, lay a foundation for the comprehensive development and utilization of non-medicinal parts of the ligusticum wallichii, and realize the waste of traditional Chinese medicine resources.
Disclosure of Invention
The invention aims to provide an application of a phthalide dimer compound, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof in preparing vasodilation drugs.
The invention provides a use of a phthalide dimer compound, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof, in the preparation of a vasodilator drug, the phthalide dimer compound comprising 1 or 2 spiro atoms, the phthalide dimer compound being formed by cycloaddition of two phthalide monomers by [ 2+2 ], wherein the two phthalide monomers are each independently selected from the following structures:
further, the phthalide dimer compound comprises a structure shown in the following formulas I to III:
further, the phthalide dimer compound comprises a structure shown in the following formulas IV and V:
the invention provides a method for preparing the phthalide dimer compound, which comprises the following steps:
step 1: pulverizing stem and leaf of rhizoma Ligustici Chuanxiong, extracting with 95% ethanol, concentrating the ethanol extractive solution under reduced pressure to obtain extract;
step 2: dispersing the extract in the step 1 with water, sequentially extracting with petroleum ether, ethyl acetate and n-butanol respectively, and concentrating under reduced pressure to obtain petroleum ether, ethyl acetate and n-butanol parts;
step 3: separating the petroleum ether part in the step 2 by an MCI chromatographic column, eluting with methanol and water=90:10, concentrating the eluent, passing through a 200-300 mesh silica gel column, gradient eluting with petroleum ether and ethyl acetate=99:1, 98:2,95:5,90:10,80:20,60:40,50:50 and 1:99, detecting and combining the same spot-like components by TLC, and concentrating to obtain components Fr.1-8;
step 4: separating the component Fr3 containing the compound of the formula I obtained in the step 3 by a silica gel column, performing gradient elution by using normal hexane to acetone=10:0, 8:2, 6:4, 4:6, 2:8 and 0:10, detecting and combining similar components by using TLC, and concentrating to obtain a component Fr.3.1-3.6;
step 5: separating and purifying the component Fr.3.5 containing the compound of the formula I in the step 4 by semi-preparative HPLC, and concentrating to obtain the compound of the formula I;
step 6: passing the component Fr5 containing the compound of formula II in step 3 through a gel chromatographic column as eluent: CHCl (CHCl) 3 Meoh=2:3, separation, TLC detection, combining similar fractions to give three fractions fr.5.1-fr.5.3;
step 7: subjecting the component Fr5.2 containing the compound of formula II in step 6 to semi-preparative HPLC to obtain the compound of formula II;
step 8: passing component Fr5.3 containing the compound of formula III in step 6 through C 18 Medium pressure preparative chromatography eluting with MeOH H 2 O=70:30-100:0, gradient elution, TLC detection, combining similar components to obtain fr.5.3.1-fr.5.3.4;
step 9: the fraction fr.5.3.4 containing the compound of formula III in step 8 is purified and separated by semi-preparative HPLC to give the compound of formula III.
Further, in step 5, the mobile phase is: CH (CH) 3 CN:H 2 O=70:30, flow rate of 3.0mL/min; detection wavelengths are 208 and 254nm; the retention times of the compounds of formula I are: 27.6min;
in step 7, the mobile phase is: CH (CH) 3 CN:H 2 O=70:30, flow rate of 3.0mL/min; detection wavelengths are 208 and 254nm; chemical conversion of IIThe retention time of the compound was: 32.4min;
in step 9, the mobile phase is: CH (CH) 3 CN:H 2 O=70:30, flow rate of 3.0mL/min; detection wavelengths are 208 and 254nm; the retention time of the compound of formula III is: 33.8min.
The invention also provides a method for preparing the phthalide dimer compound, and the compound of the formula II is separated by chiral HPLC to obtain the compound of the formula IV and the compound of the formula V.
Further, the chiral column is: CHIRALPAK IC,4.6 μm, 250X 4.6mm; the mobile phase is: n-hexane: ethanol=90:10, flow rate: 0.8mL/min; the retention time of the compound of formula IV is: 21.93min, retention time of the compound of formula V: 24.34min.
Further, the vasodilator in the application of the invention is a calcium ion channel Cav1.2 inhibitor.
Further, the vasodilator in the application of the invention is a medicine for treating cardiovascular diseases.
Further, the cardiovascular disease is hyperlipidemia, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction and hypertension.
The compounds of the formulas I-V have the function of dilating blood vessels, and have better activity than the contrast monophthalide compound. Meanwhile, the chiral resolution is carried out on the compound of the formula II, and the obtained compounds of the formula IV and the formula V have remarkable effect of inhibiting Cav1.2, wherein the activity of the compound of the formula IV for inhibiting Cav1.2 is superior to that of the compound of the formula V. The compound can be used for preparing a Cav1.2 inhibitor, can also be used for preparing a vasodilation medicament, and can be further used for preparing a medicament for treating cardiovascular diseases, and the compound plays a role in vasodilation by antagonizing the action of a Cav1.2 receptor, so that a new choice is provided for clinically screening and/or preparing the vasodilation medicament, and a new molecular template is provided for designing a novel calcium antagonist medicament, thereby having wide clinical application prospect.
Unless stated to the contrary, the terms used in the specification and claims have the following meanings.
The term "spiro atom" as used herein refers to two rings sharing only one atom, and the shared atom is a spiro atom.
The "[ 2+2 ] cycloaddition" refers to a compound with four-membered stable ring formed by combining two molecules of olefin, small molecules are not eliminated, delta bonds are only generated, and the delta bonds are not broken. Specific examples in the present invention are phthalide dimers in which the double bonds in two phthalide monomers are joined by a four-membered ring formed by [ 2+2 ] cycloaddition.
The compound of the formula I is represented by a code CX31 in a study, the code CX51 in a compound of the formula II in a study, the code CX59 in a compound of the formula III in a study, the code CX51a in a compound of the formula IV in a study, and the code CX51b in a compound of the formula V in a study.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
FIG. 1 chiral resolution chromatograms of compounds of formula IV and formula V;
FIG. 2 is an IR diagram of a compound of formula I;
FIG. 3 is a hydrogen spectrum of a compound of formula I;
FIG. 4 is a carbon spectrum of a compound of formula I;
FIG. 5 DEPT spectra of compounds of formula I;
FIG. 6 HSQC spectra of compounds of formula I;
FIG. 7 is a HMBC spectrum of a compound of formula I;
FIG. 8 Compounds of formula I 1 H- 1 H COSY profile;
FIG. 9 NOSEY spectra of compounds of formula I;
FIG. 10 is a high resolution mass spectrum of a compound of formula II;
FIG. 11 is an IR diagram of a compound of formula II;
FIG. 12 is a hydrogen spectrum of a compound of formula II;
FIG. 13 carbon spectrum of compound of formula II;
FIG. 14 DEPT spectra of compounds of formula II;
FIG. 15 HSQC spectra of compounds of formula II;
FIG. 16 is a HMBC profile of a compound of formula II;
FIG. 17 compounds of formula II 1 H- 1 H COSY profile;
FIG. 18 NOSEY spectrum of a compound of formula II;
FIG. 19 is a two-dimensional correlation diagram of compounds of formula II;
FIG. 20 is a high resolution mass spectrum of a compound of formula III;
FIG. 21 is an IR diagram of a compound of formula III;
FIG. 22 is a hydrogen spectrum of a compound of formula III;
FIG. 23 carbon spectrum of a compound of formula III;
FIG. 24 DEPT spectra of compounds of formula III;
FIG. 25 HSQC spectra of compounds of formula III;
FIG. 26 is a HMBC profile of a compound of formula III;
FIG. 27 compounds of formula III 1 H- 1 H COSY profile;
FIG. 28 NOSEY spectra of compounds of formula III;
FIG. 29 is a two-dimensional correlation diagram of compounds of formula III;
FIG. 30 ECD diagrams of compounds of formula IV and formula V;
FIG. 31 changes in the diastolic rate and vascular tone of KCl pre-contracted vascular rings with Compounds 3-Butylidenephthalide, CX31 (Compound of formula I), CX51 (Compound of formula II) and CX59 (Compound of formula III), P compared to the model group<0.05,**P<0.01,***P<0.001(n＝6)；
FIG. 32 Compound of formula IV (Compound CX51 a) versus Cav1.2 Current inhibition effect curve (IC 50 )；
FIG. 33 is a graph of the current-inhibiting effect of a compound of formula IV (compound CX51 a) on different cells;
FIG. 34 Current-inhibiting effect of Compound of formula V (Compound CX51 b) on different cells;
FIG. 35 Current-inhibiting effect of the compound of formula III (compound CX 59) on different cells.
Detailed Description
EXAMPLE 1 preparation of Compounds of formulas I-V
1. Experimental instrument and reagent
1 laboratory apparatus
Avance 400MHz superconducting nmr (Bruker, germany); avance 600MHz superconducting nmr (Bruker, germany); a Synapt G2 HDMS mass spectrometer (Waters company); perkin-Elmer 341plus polarimeter (Perkin Elmer Co., U.S.A.); LC50 medium-high pressure liquid phase (sieboldii beijing technologies limited); chromatographic column (COSMOS, choiester,10id×250 nm); electronic balance (model FA2004B, shanghai plain scientific instruments limited); an ex vivo tissue organ constant temperature perfusion system (PL 3508B6/C-V Panlab 8Chamber Organ Bath System); ultra-pure water of the UpUPT series (Chengdu Upelectronic products Co., ltd.); adjustable pipettor: (Thermo Fisher Scinentific).
2 experiment reagent
Sephadex LH-20 chromatographic packing (Pharmacia, switzerland); MCI resin (mitsubishi chemical company of japan); silica gel GF254 thin layer plate (Qingdao ocean chemical plant); 200-300 mesh column chromatography silica gel (Qingdao ocean chemical plant); chromatographic pure methanol (TEDIA company, usa); deuterated reagent (CIL Co., USA). Other reagents were analytically pure (colone chemicals limited, adult city); golopami (Me) (Methoxyverapamil, me, jiangsu Rui year front drug Co., ltd., approval paper number: H32020683); SD rats, SPF grade, both male and female, weight 200-240 g, supplied by Sichuan Chengdu Shuo Biotech Co., ltd (SCXK 2015-030). The raising temperature is 20-25 ℃, and the lighting and ventilation environment are naturally regulated.
Stem and leaf of Ligusticum wallichii (Ligusticum chuanxiong Hort.) was collected from Dongpo area of Mitsui, sichuan, 4 months in 2018, and the specimen was found in the university of Chengdu traditional Chinese medicine, traditional Chinese medicine chemical 1001 laboratory.
2. Experimental details
1 preparation of Compounds
1.1 extraction and isolation of Compounds (preparation of Compounds of formulae I to III)
1) Pulverizing natural and shade-dried stem and leaf of Ligusticum chuanxiong (20 kg)) into coarse powder, percolating with 95% ethanol, and concentrating under reduced pressure to obtain extract.
2) Sequentially extracting with petroleum ether, ethyl acetate and n-butanol, and concentrating under reduced pressure to obtain petroleum ether, ethyl acetate and n-butanol.
3) Petroleum ether fraction (0.5 kg) was eluted with methanol/water=90:10 by MCI chromatography, and the decolorized, concentrated solution was eluted with a gradient of silica gel column (200-300 mesh, PE-EtOAc (99:1, 98:2,95:5,90:10,80:20,60:40,50:50,1:99, v/v) to give fractions Fr.1-8, respectively.
4) Wherein, component fr.3 (40 g) was subjected to gradient elution by silica gel column separation (n-hexane: acetone=10:0, 8:2, 6:4, 4:6, 2:8, 0:10 gradient elution) to obtain 6 parts (fr.3.1-fr.3.6).
5) Fr.3.5 fractions were subjected to semi-preparative HPLC (CH 3 CN-H 2 O,70:30, v/v,3.0mL/min; detection wavelength: 208,254 nm) to give a compound of formula I, CX31 (t) R 27.6min,8.4mg)。
6) Component Fr.5 (60 g) was purified by gel chromatography (CHCl) 3 MeOH, 2:3, v/v) gives three components Fr.5.1-Fr.5.3.
7) Fr.5.2 by semi-preparative HPLC (MeOH-H 2 O,70:30, v/v,3.0mL/min; detection wavelength: 208 and 254 nm) to give a compound of formula II, CX51 (t) R 32.4min,8.6mg)。
8) Fr.5.3 fraction was taken through C 18 Medium pressure preparative chromatography (MeOH: H) 2 O,70:30-100:0, v/v) gradient elution to give fr.5.3.1-fr.5.3.4.
9) Fr.5.3.4 fractions were purified by semi-preparative HPLC (CH 3 CN-H 2 O,70:30, v/v,3.0mL/min; detection wavelength: 208 and 254 nm) to give a compound of formula III, CX59 (t) R 33.8min，8.6mg)。
1.2 chiral resolution of Compounds of formula II CX51 (preparation of Compounds of formulae IV and V)
Resolution of compound CX51 of formula II by chiral HPLC gives compound CX51a of formula IV and compound CX51b of formula V.
The chiral column is: CHIRALPAK IC (Lot. No. IC00CE-XC 014), 4.6 μm, 250X 4.6mm. The mobile phase is: n-hexane-ethanol (90:10) at a flow rate of 0.8mL/min. CX51a retention time is: 21.93min, CX51b retention time of 24.34min. (the chromatogram is shown in FIG. 1)
2 structural identification
2.1 Compounds of formula I CX31
Basic physical and chemical properties: colorless crystals, molecular formula: c (C) 24 H 26 O 4 Molecular weight: 378.1988, is easily dissolved in organic solvents such as methanol, dichloromethane, ethyl acetate and the like.
Structural data and identification:
optical rotation data: [ alpha ]] 25 D ＝-2.5°(c 0.05,MeOH)。
Ultraviolet spectral data: UV (MeOH) λmax (log epsilon) =230 (0.22) nm
Infrared spectral data: IR:2961,2923,2853,2813,1751,1645,1576,1463,1411,1260,1061cm -1 (the map is shown in FIG. 2).
The nuclear magnetic data and attribution are shown in Table 1 (the patterns are shown in figures 3-9).
TABLE 1 Nuclear magnetic data and assignment of Compounds CX31 of formula I
The above spectral data are consistent with reported compound Diangeliphthalide A of the literature (Zou J, chen G D, zhao H, et al, triangeliphtalides A-D: bioactive phthalide trimers with new skeletons from Angelica sinensis and their production mechanism [ J ]. Chemical Communications,2019,55.).
2.2 Compounds of formula II CX51
Basic physical and chemical properties: yellow oil, molecular formula: c (C) 24 H 28 O 4 Molecular weight: 380.20, is easily dissolved in organic solvents such as methanol, dichloromethane, ethyl acetate and the like.
Structural data and identification:
[α] 25 D ＝-3.38°(c 0.04,MeOH)。
HRESIMS：m/z 381.2060[M+H] + prompt molecular formula C 24 H 28 O 4 (calcd for C 24 H 29 O 4 381.2060) (see figure 10 for a map).
UV(MeOH)λmax(logε)＝286(0.51)nm。
Infrared spectral data: IR:2981,2903,1748, 1720, 1402,1250,1067,894cm -1 (see FIG. 11 for a map).
The nuclear magnetic data and attribution are shown in table 2 (maps are shown in fig. 12-18), and the two-dimensional correlation diagram is shown in fig. 19. The planar structure is similar to that of the compound tokiaerialide reported in the literature (Uto, T.; tung, N.H.; taniyama, R.; miyanowaki, T.; morinaga, O.; shoyama, Y.; anti-inflammatory Activity of Constituents Isolated from Aerial Part of Angelica acutiloba Kitagawa. Photon Res 2015,29 (12), 1956-1963.)
TABLE 2 Nuclear magnetic data and assignment of Compounds CX51 of formula II
2.3 Compounds of formula III CX59
Basic physical and chemical properties: yellow oil, molecular formula: c (C) 24 H 28 O 4 Molecular weight: 380.19, is easily dissolved in organic solvents such as methanol, dichloromethane, ethyl acetate and the like.
Structural data and identification:
[α] 25 D ＝-5.38°(c 0.04,MeOH)。
UV(MeOH)λmax(logε)＝286(0.50)nm。
HRESIMS m/z 381.2057[M+H] + prompt molecular formula C 24 H 28 O 4 (calcd for C 24 H 29 O 4 381.2060) (see figure 20 for a map).
Infrared spectral data: IR:2981,2903,1748, 1720, 1402,1250,1067,894cm -1 (see FIG. 21 for a map).
The nuclear magnetic data and attribution are shown in Table 3 (maps are shown in FIGS. 22-28), and the two-dimensional correlation map is shown in FIG. 29. The planar structure is similar to that of the reported compound neodiligustilide. ( Chen, q.c.; lee, j.; jin, w.; you, u.; kim, h.; lee, i.s.; zhang, x.; song, k.; seong, y; bae, k., cytotoxic constituents from angelicaesinensis radix. Arch Pharm Res 2007,30 (5), 565-9. )
TABLE 3 Nuclear magnetic data and assignment of Compounds CX-59 of formula III
2.4 Compounds CX51a and CX51b of formula IV
2.4.1 Compounds of formula IV
[α] 25 D ＝-23.4°(c 0.04,MeOH),
ECD(c 0.01,MeOH)＝Δε 214 +26.37,Δε 247 –5.77。
2.4.2 Compounds of formula V
[α] 25 D ＝+68.1°(c 0.04,MeOH),
ECD(c 0.01,MeOH)＝Δε 214 –15.37,Δε 249 +3.72 (map see FIG. 31).
From the above data, and FIG. 30, it can be determined that compound CX51a of formula IV is configured as (3R, 8S,3'aR,7' aR) -51a, whereas compound 51b of formula V is configured as: (3S, 8R,3'aS,7' aS) as follows.
Test example 1 vasodilation experiment
1 method
The rat cervical dislocation is sacrificed, the thoracic aorta is taken out after the thoracic cavity is opened, and the thoracic aorta is cut into a vascular ring with the length of about 4mm and placed in O 2 Saturated 4 ℃ K-H solution [ (g/L), naCl 6.92,KCl 0.35,CaCl 2 0.28,KH 2 PO 4 0.16,MgSO 4 0.14,NaHCO 3 2.00,Glucose 1.82,EDTA 0.009]Constant temperature of 37 ℃. Connecting an in-vitro tissue perfusion model and a Power Lab data analysis system, regulating the resting tension to be 1g, and continuously introducing 94.6% O 2 +5.4％CO 2 The K-H solution is replaced every 15min, the process is repeated for two times, after balancing for 60min, KCl (60 mmol/L) is used for stimulating vascular ring, the K-H solution is used for flushing for three times when the tension reaches the plateau value, each time is separated for 5min, after the state is restored to the basic state, the process is stabilized for 30min, and the process is repeated for 2 times. After the 3 rd time of pre-shrinking of the vascular ring to reach a plateau value and stabilizing, adding 2.4-12 mu mol/L of samples in a bath in a cumulative way, adding 2 mu L of total volume, and adding an equal volume of DMSO into a blank group. The vasodilation effect profile of the test compounds (3-Butylidenephthalide, CX, CX51, CX 59) was recorded with golopamide (Me) as a positive drug control and repeated 6 times per group.
2 statistical method
The effect of each concentration of the compound on the magnitude of vasoconstriction was calculated with the maximum systolic tension due to KCl (60 mmol/L) being 100%. The experimental data adopts the change of blood vessel tension value to reflect the action of the medicine, and the unit is g. SPSS 21.0 statistical software is adopted for analysis and treatment, and P is less than 0.05, so that the method has statistical significance.
Calculation formula of vasodilation rate:
results of vasodilatory Activity
The blank group had no significant effect on potassium chloride (KCl) -induced rat thoracic aortic annulus contractions (P)>0.05 Each of the administration groups was able to lower the tension value of the vascular ring. Each concentration of golopamide (Me) can significantly relax the vascular ring (P)<0.001 The highest concentration diastolic rate was 120%. The test compounds all have the effect of dilating the vascular ring and exhibit concentration dependence. The highest concentration (12. Mu. Mol/L) of the reference Z-3-butenyl phthalide (abbreviated Bu) has a diastole of 40%, wherein the highest concentration (12. Mu. Mol/L) of CX31 has a diastole of 65.1%, and IC 50 =8.81 μmol/L; CX51 maximum concentration (12. Mu. Mol/L) diastole 96.1%, IC 50 =5.87 μmol/L; CX59 maximum concentration (12. Mu. Mol/L) diastole 93.4%, IC 50 =6.19 μmol/. See fig. 31.
From the above results, the phthalide dimer compounds of the present invention have vasodilating effect in all of the formulae I to V (formulae IV and V are chiral resolution of formula II). And the activity of the phthalide dimer compound is better than that of the monophthalide (Z-3-butenyl phthalide).
Test example 2 electrophysiological experiments
1 instrument and reagents
All instruments and reagents for this experiment are commercially available.
2 cell culture
In this experiment, a CHO cell line stably expressing cav1.2 channels was used, and the cell line was constructed by the laboratory of biotechnology, inc.
(1) The CHO cell line stably expressing cav1.2 channels was cultured in DMEM medium containing 10% fetal bovine serum and 0.8mg/mL G418 at 37 ℃ and carbon dioxide concentration of 5%.
(2)Cell passage: the old medium was removed and washed once with PBS, then 1mL of TrypLE was added TM Express solution, incubated at 37℃for 0.5min (CHO cells 1.5 min). When the cells were detached from the bottom of the dish, 5mL of complete medium, pre-warmed at 37℃was added. The cell suspension was gently swirled with a pipette to separate the aggregated cells. The cell suspension was transferred to a sterile centrifuge tube and centrifuged at 1000rpm for 5min to collect the cells. Expanding or maintaining culture, inoculating cells into 6cm cell culture dishes, wherein the cell culture dishes are inoculated with 2.5×10 cells 5 cells (final volume: 5 mL).
(3) To maintain the cell's electrophysiological activity, the cell density must not exceed 80%.
(4) Patch clamp detection, prior to experiment, cells were assayed with TrypLE TM Express separation, 3 x 10 3 Cells were spread on cover slips and cultured in 24 well plates (final volume: 500. Mu.L), and after 24 hours, experimental detection was performed.
3 Whole cell patch clamp recordings
Extracellular fluid: 140mM TEA-Cl,2mM MgCl 2 ·6H 2 O，10mM CaCl 2 ·2H 2 O,10mm hepes,5mm md-glucose, TEA-OH adjusts ph=7.4.
Intracellular fluid: 120mMCsCl,1mM MgCl 2 ·6H 2 O，10mM HEPES，10mM EGTA，0.3mM Na 2 GTP,4mM Mg-ATP, csOH adjusts ph=7.2.
The voltage stimulation protocol for patch clamp recording whole cell cav1.2 calcium current is as follows: after the whole cell seal is formed, the cell membrane voltage is clamped at-60 mV. The clamping voltage is divided from-60 mV to +10mV for 0.3s, data are repeatedly collected every 20s, and the effect of the drug on the current peak of Cav1.2 is observed. Experimental data was collected by EPC-10 amplifier (HEKA) and stored in PatchMaster (HEKA) software.
Capillary glass tubes (BF 150-86-10,Sutter Instruments) were drawn into recording electrodes using a microelectrode drawing instrument (P97, sutter Instruments). Manipulation of the microelectrode manipulator (MP 285, sutter Instuments/card-C-S, MCI instruments) under a microscope (IX 71, olympus/AE31EF-INV, motic (China)) the recording electrode was contacted with the cell, and negative pressure aspiration was applied to form a GΩ seal. After forming G omega sealing, carrying out rapid capacitance compensation, then continuing to give negative pressure, sucking and breaking cell membranes, and forming a whole cell recording mode. Then, compensation of the slow capacitor is performed, the film capacitor and the series resistance are recorded, and no leakage compensation is given.
When the administration was started after the current recorded by the whole cells was stabilized, the next concentration was detected after each drug concentration was applied to 5min (or the current was stabilized), and the test compounds (CX 59, CX51a, CX51 b) were detected at a plurality of concentrations. The coverslip with cells laid thereon was placed in a recording cell in an inverted microscope, and the test compound and the external liquid containing no compound were sequentially flowed through the recording cell from low concentration to high concentration by gravity perfusion to act on the cells, and liquid exchange was performed in the recording using a vacuum pump. The current detected by each cell in the compound-free external fluid served as its own control. Multiple cells were independently and repeatedly tested. All electrophysiological experiments were performed at room temperature.
4 data quality criteria
The following criteria are used to determine whether the data is acceptable:
(1) Electrode resistance <5MΩ
(2) Sealing resistance >1G omega
(3) The start of the access resistance is <15MΩ
(4) The end of the access resistance is less than 15MΩ
(5) There is no significant spontaneous decay in current
5 data analysis
The current after each drug concentration was first normalized to the current for the blankThe inhibition rate or increase ratio corresponding to each drug concentration is then calculated. Average and standard errors were calculated for each concentration and the semi-inhibitory concentration for each compound was calculated using the following equation: />
Non-linear fitting of dose-dependent effects was performed with the above equation, where C represents drug concentration, IC 50 H represents the Hill coefficient for the half-inhibitory concentration. Curve fitting and IC 50 Is done using IGOR software.
6 electrophysiological experimental results
The present study uses whole cell patch clamp to record ion channel currents of CHO cell lines stably expressing cav1.2 and to analyze the effect of the compounds of the invention on cav1.2 channels. The experimental results show that the compound (CX 51 a) in the formula IV and the compound (CX 51 b) in the formula V have remarkable Cav1.2 inhibition, wherein the CX51a has remarkable inhibition, and the IC50 is 7.5 mu M+/-1.6 mu M; other compounds do not act significantly. The results are shown in tables 4 and 5, and FIGS. 32 to 35.
TABLE 4 inhibition ratio of samples (CX 59, CX51a, CX51 b) to Cav1.2 current
TABLE 5 inhibition ratio of test sample (CX 51 a) to Cav1.2 current and IC 50 Results
In conclusion, the compounds of the present invention, formulas I-V, all have vasodilatory effects and are more active than the control monophthalide compounds. Meanwhile, the chiral resolution is carried out on the compound of the formula II, and the obtained compounds of the formula IV and the formula V have remarkable effect of inhibiting Cav1.2, wherein the activity of the compound of the formula IV for inhibiting Cav1.2 is superior to that of the compound of the formula V. The compound can be used for preparing a Cav1.2 inhibitor, can also be used for preparing a vasodilation medicament, and further can be used for preparing a medicament for treating cardiovascular diseases, and has wide clinical application prospect.
Meanwhile, the compound provides a direction for searching lead compounds for treating cardiovascular diseases. Through development and utilization research on overground biological resources of ligusticum wallichii, the chemical component library of the stem and leaf of ligusticum wallichii is further enriched, a foundation is laid for screening vascular expanding seedling compounds, the 'integrated dual-purpose' of traditional Chinese medicine resources is realized, and the sustainable development of the traditional Chinese medicine resources is facilitated.
Claims (7)
1. Use of a phthalide dimer compound or a salt thereof in the preparation of a vasodilator drug, wherein the phthalide dimer compound has a structure shown in the following formulas I-III:
2. use according to claim 1, characterized in that: the phthalide dimer compound has a structure shown in a formula IV and a formula V:
3. a process for preparing the phthalide dimer compound of claim 1, characterized in that:
step 1: pulverizing stem and leaf of Ligusticum chuanxiong, extracting with 95% v/v ethanol, concentrating the ethanol extractive solution under reduced pressure to obtain extract;
step 2: dispersing the extract in the step 1 with water, sequentially extracting with petroleum ether, ethyl acetate and n-butanol respectively, and concentrating under reduced pressure to obtain petroleum ether, ethyl acetate and n-butanol parts;
step 3: separating the petroleum ether part in the step 2 by an MCI chromatographic column, eluting by adopting a methanol-water volume ratio of 90:10, concentrating an eluent, passing through a 200-300 mesh silica gel column, carrying out gradient elution by adopting petroleum ether-ethyl acetate volume ratios of 99:1,98:2,95:5,90:10,80:20,60:40,50:50 and 1:99, detecting and combining the same spot-like components by utilizing TLC, and concentrating to obtain components Fr.1-8;
step 4: separating the component Fr3 containing the compound of the formula I obtained in the step 3 by a silica gel column, performing gradient elution by using n-hexane to acetone in a volume ratio of 10:0, 8:2, 6:4, 4:6, 2:8 and 0:10, detecting and combining similar components by using TLC, and concentrating to obtain a component Fr.3.1-3.6;
step 5: separating and purifying the component Fr.3.5 containing the compound of the formula I in the step 4 by semi-preparative HPLC, and concentrating to obtain the compound of the formula I;
step 6: passing the component Fr5 containing the compound of formula II in step 3 through a gel chromatographic column as eluent: CHCl (CHCl) 3 MeOH volume ratio 2:3, separation, TLC detection, combining similar components to obtain three components Fr.5.1-Fr.5.3;
step 7: subjecting the component Fr5.2 containing the compound of formula II in step 6 to semi-preparative HPLC to obtain the compound of formula II;
step 8: passing component Fr5.3 containing the compound of formula III in step 6 through C 18 Medium pressure preparative chromatography eluting with MeOH H 2 The O volume ratio is 70:30-100:0, gradient elution and TLC detection are carried out, and similar components are combined to obtain Fr.5.3.1-Fr.5.3.4;
step 9: purifying and separating the component Fr.5.3.4 containing the compound of the formula III in the step 8 by semi-preparative HPLC to obtain the compound of the formula III;
in step 5, the mobile phase is: CH (CH) 3 CN:H 2 The O volume ratio is 70:30, and the flow rate is 3.0mL/min; detection wavelengths are 208 and 254nm; the retention times of the compounds of formula I are: 27.6min;
in step 7, the mobile phase is: CH (CH) 3 CN:H 2 The O volume ratio is 70:30, and the flow rate is 3.0mL/min; detection wavelengths are 208 and 254nm; the retention time of the compound of formula II is: 32.4min;
in step 9, the mobile phase is: CH (CH) 3 CN:H 2 The O volume ratio is 70:30, and the flow rate is 3.0mL/min; detection wavelengths are 208 and 254nm; the retention time of the compound of formula III is: 33.8min.
4. A process for preparing the phthalide dimer compound of claim 2, characterized in that: resolving the compound of formula II according to claim 1 by chiral HPLC to give a compound of formula IV and a compound of formula V;
the chiral column is: CHIRALPAK IC,4.6 μm, 250X 4.6mm; the mobile phase is: n-hexane: ethanol=90:10, flow rate: 0.8mL/min; the retention time of the compound of formula IV is: 21.93min, retention time of the compound of formula V: 24.34min.
5. Use according to claim 1 or 2, characterized in that: the vasodilator is a calcium ion channel Cav1.2 inhibitor.
6. Use according to claim 1 or 2, characterized in that: the vasodilator is a medicine for treating cardiovascular diseases.
7. Use according to claim 6, characterized in that: the cardiovascular diseases are hyperlipidemia, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction and hypertension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911422088.5A CN111018876B (en) | 2019-12-31 | 2019-12-31 | Application of phthalide dimer in preparation of vasodilation drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911422088.5A CN111018876B (en) | 2019-12-31 | 2019-12-31 | Application of phthalide dimer in preparation of vasodilation drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111018876A CN111018876A (en) | 2020-04-17 |
| CN111018876B true CN111018876B (en) | 2023-08-04 |
Family
ID=70201827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911422088.5A Active CN111018876B (en) | 2019-12-31 | 2019-12-31 | Application of phthalide dimer in preparation of vasodilation drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111018876B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089594A1 (en) * | 2007-01-19 | 2008-07-31 | Fei Chen | Use of phthalide dipolymers for antitumor |
-
2019
- 2019-12-31 CN CN201911422088.5A patent/CN111018876B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089594A1 (en) * | 2007-01-19 | 2008-07-31 | Fei Chen | Use of phthalide dipolymers for antitumor |
Non-Patent Citations (1)
| Title |
|---|
| Direct and Metal-Catalyzed Photochemical Dimerization of the Phthalide (Z)-Ligustilide Leading to Both [2 + 2] and [4 + 2]Cycloadducts: Application to Total Syntheses of Tokinolides A−C and Riligustilide;Bingbing Sheng;《Org. Lett.》;20190805;第21卷;6295−6299页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111018876A (en) | 2020-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bai et al. | HSQC-based small molecule accurate recognition technology discovery of diverse cytotoxic sesquiterpenoids from Elephantopus tomentosus L. and structural revision of molephantins A and B | |
| CN111018876B (en) | Application of phthalide dimer in preparation of vasodilation drugs | |
| CN109942649A (en) | A kind of indoles glycosides compound and its purification methods and uses | |
| CN104628531B (en) | A kind of compound S J-11 extracting Cong Shan Kashihara and preparation method thereof and application | |
| CN110746421B (en) | Extraction method and application of indole monoterpene compound | |
| CN108403672A (en) | Patchouli alcohol is preparing the purposes in preventing renal damage drug | |
| CN115894414B (en) | Amide lignans compound prepared from white English, preparation method and application thereof | |
| CN115160335B (en) | Phthalide dimer and preparation method and application thereof | |
| CN111116601B (en) | Novel phthalide dimer framework compound and preparation method and application thereof | |
| CN111471030B (en) | Phthalide dimer new framework compound and preparation method and application thereof | |
| CN101190259A (en) | Southern magnolia total lactone extract and preparation method and application thereof | |
| CN113061124B (en) | Sesquiterpene dimer compound, and preparation method, application and pharmaceutical composition thereof | |
| CN103183597A (en) | Diaryl neptanone compound having antineoplastic activity, preparing method and application | |
| CN106397530A (en) | Condensed ring-type cucurbitane triterpenoid and its preparation method and use | |
| CN112812085A (en) | A pair of compounds A, B extracted from Cornus officinalis, and its preparation method and application | |
| CN109206392B (en) | Coumarin compound and preparation method and application thereof | |
| CN114853712B (en) | Chromane or chromene type hetero-terpenoid, and extraction method and application thereof | |
| CN110776409A (en) | Method for extracting pterocarpus indicus and application of extract in antitumor drugs | |
| CN110638822A (en) | Albizzia julibrissin glycoside compound for promoting endothelial cell proliferation and application thereof | |
| CN117143100B (en) | Analgesic compound with Nav1.2 inhibition effect in radix Arnafae, and preparation and application thereof | |
| CN112300185B (en) | Alkaloid compound with reduced hepatotoxicity, and preparation method and application thereof | |
| CN115073403B (en) | Preparation method and application of three compounds separated from cornel wine and having heart failure prevention and treatment effects | |
| CN114805465B (en) | Triterpene compound, preparation method and application thereof | |
| CN114436983B (en) | Oleraze and Oleraoxazine acid in purslane and extraction and separation method thereof | |
| Nona et al. | Effect of deuterium oxide on the culturing of Penicillium janczewskii II. Isolation of fully deuterated griseofulvin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No.279, Donghe East Road, Zhihe Town, Pengzhou City, Chengdu, Sichuan 610000 Applicant after: SICHUAN NEW GREEN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Applicant after: Chengdu University of Traditional Chinese Medicine Address before: 610000 No. 1166 Liutai Avenue, Wenjiang District, Chengdu City, Sichuan Province Applicant before: Chengdu University of Traditional Chinese Medicine Applicant before: SICHUAN NEW GREEN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |